A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
Jonathan W. Goldman(University of California, Los Angeles), Luis Paz‐Ares(Universidad Complutense de Madrid)
Cited by 51
Related Papers
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy
|Journal of Thoracic Oncology|2019|71